Rucaparib - Clovis Oncology

Drug Profile

Rucaparib - Clovis Oncology

Alternative Names: AG-014699; AG-14699; CO-338; PF-01367338; PF-1367338; Rubraca; Rucaparib phosphate

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research UK
  • Developer Bristol-Myers Squibb; Cancer Research UK; Clovis Oncology; Roche; UNICANCER; University of California at San Francisco
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Indoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Preregistration Fallopian tube cancer; Peritoneal cancer
  • Phase III Prostate cancer
  • Phase II Breast cancer; Pancreatic cancer; Urogenital cancer
  • Phase I Gynaecological cancer; Solid tumours
  • Suspended Malignant melanoma

Most Recent Events

  • 08 Mar 2018 Clovis Oncology receives notice of allowance from the USPTO for high dosage strength rucaparib camsylate formulations in USA
  • 26 Feb 2018 Phase-II clinical trials in Urogenital cancer (Late-stage disease) in USA (PO) (NCT03397394; 9234274)
  • 26 Feb 2018 Bristol-Myers Squibb and Clovis Oncology plan a phase III ATHENA trial of rucaparib in combination with nivolumab as first-line maintenance therapy for Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Late-stage disease, Second-line therapy, Newly diagnosed) in Europe and USA in 1H 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top